Abliva AB is a pharmaceutical company based in Lund that specializes in developing medicines for primary mitochondrial diseases. The company is dedicated to improving mitochondrial health and addressing unmet medical needs in this area. Abliva focuses on research and development, employing innovative approaches to treatment and therapy for mitochondrial disorders.
The company conducts clinical studies, including the FALCON Study, to evaluate the efficacy and safety of its therapies. Abliva collaborates with healthcare professionals and researchers to advance scientific understanding of mitochondrial diseases. Through its patient-centric solutions, the company aims to enhance the quality of life for individuals affected by these conditions.